Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 866-874

  Chan, Wan ^a   Luo, Hai Bin ^a   Zheng, Yufang ^a   Cheng, Yuen Kit ^a   Cai, Zongwei ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYARISTOLACTAM; ARISTOLOCHIC ACID; ARISTOLOLACTAM; DRUG METABOLITE; N HYDROXYARISTOLACTAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOMER; MALE; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; TANDEM MASS SPECTROMETRY;

ANIMALS; ARISTOLOCHIC ACIDS; BIOTRANSFORMATION; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 34249068309     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013979     Document Type: Article

References (28)

1. Arlt VM, Stiborova M, and Schmeiser HH (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17:265-277.
2. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18:1063-1067.
3. Chan W, Cui L, Xu GW, and Cai ZW (2006) Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1755-1760.
4. Fu PP, Chou MW, Miller DW, White GL, Helflich RH, and Beland FA (1985) The orientation of the nitro substituent predicts the direct-acting bacterial mutagenicity of nitrated polycyclic aromatic hydrocarbons. Mutat Res 143:173-181.
5. Hasegawa Y, Muraki T, Tokuyama T, Iwaki H, Tatsuno M, and Lau PCK (2000) A novel degradative pathway of 2-nitrobenzoate via 3-hydroxyanthranilate in Pseudomonas fluorescens strain KU-7. FEMS Microbiol Lett 190:185-190.
6. Hughes JB, Wang CY, and Zhang CL (1999) Anaerobic biotransformation of 2,4-dinitrotoluene and 2,6-dinitrotoluene by Clostridium acetobutylicum: a pathway through dihydroxylamino intermediates. Environ Sci Technol 33:1065-1070.
7. 18 stationary phase composition for non-cogeneric solutes. J Chromtogr 352:141-155.
8. Kato R, Oshima T, and Takanaka A (1969) Studies on the mechanism of nitro reduction by rat liver. Mol Pharmacol 5:487-498.
9. Krumbiegel G, Hallensleben J, Mennicke WH, and Rittmann N (1987) Studies on the metabolism of Aristolochic acids I and II. Xenobiotica 17:981-991.
10. Kupchan MS and Doskotch RW (1962) Tumor inhibitors, I. Aristolochic acid, the active principle of Aristolochia indica. J Med Pharm Chem 5:657-659.
11. Mengs U (1988) Tumor induction in mice following exposure to aristolochic acid. Arch Toxicol 61:504-505.
12. Mengs U, Lang W, and Poch JA (1982) The carcinogenic action of aristolochic acid in rats. Arch Toxicol 51:107-119.
13. Mitchelmore CL, Birmelin C, Chipman JK, and Livingstone DR (1998) Evidence for cytochrome P-450 catalysis and free radical involvement in production of DNA strand breaks by benzo-[a]pyrene and nitroaromatics in mussel (Mytilus edulis L.) digestive gland cells. Aquat Toxicol 41:193-212.
14. Niessen WMA (1999) Chromatographic Science Series Volume 79: Liquid Chromatography-Mass Spectrometry, pp 7-8, Marcel Dekker Inc., New York.
15. Ong ES, Woo SO, and Yong YL (2000) Pressurized liquid extraction of berberine and aristolochic acids in medicinal plants. J Chromatogr A 904:57-64.
16. Pfau W, Pool-Zobel BL, von der Lieth CW, and Wiessler M (1990a) The structural basic for the mutagenicity of aristolochic acid. Cancer Lett 55:7-11.
17. Pfau W, Schmeiser HH, and Wiessler M (1990b) Aristolochic acid binds covalently to exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11:313-319.
18. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11:1627-1633.
19. 6- adenylarylation of DNA by aristolochic acid II and a synthetic model for the putative proximate carcinogen. Chem Res Toxicol 4:581-586.
20. Purohit V and Basu AK (2000) Mutagenicity of nitroaromatic compounds. Chem Res Toxicol 13:673-692.
21. Rucker G and Chung BS (1975) Aristolochic acids from Aristolochia manshuriensis. Plant Med 27:68-71.
22. Schmeiser HH, Pool BL, and Wiessler M (1986) Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7:59-63.
23. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15:1187-1192.
24. Stiborova M, Frei E, Sopko B, Sopkova K, Markova V, Lankova M, Kumstyrova T, Wiessler M, and Schmeiser HH (2003) Human cytosol enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for the reductive activation by human NAD(P)H: quinone oxidoreductase. Carcinogenesis 24:1695-1703.
25. Stiborova M, Frei E, Sopko B, Wiessler M, and Schmeiser HH (2002) Carcinogenic aristolochic acid upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617-625.
26. Stiborova M, Frei E, Wiessler M, and Schmeiser HH (2001) Human cytochrome P450 enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for the reductive activation by CYP1A1 and CYP1A2. Chem Res Toxicol 14:1128-1137.
27. Sugimura T, Okabe K, and Nagao M (1966) The metabolism of 4-nitroquinoline-1-oxide, a carcinogen III. An enzyme catalyzing the conversion of 4-nitroquinoline-1-oxide to 4-hydroxyaminoquinoline-1-oxide in rat liver and hepatomas. Cancer Res 26:1717-1721.
28. Tatsumi K, Kitamura S, and Norai N (1986) Reductive metabolism of aromatic nitro compounds including carcinogens by rabbit liver preparations. Cancer Res 46:1089-1093.